Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Therapy

Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia

Leukemia volume 24, pages 699–705 (2010)Cite this article

Subjects

Abstract

Heat shock protein 90 (Hsp90) is a molecular chaperone with many oncogenic client proteins. The small-molecule Hsp90 inhibitor alvespimycin, a geldanamycin derivative, is being developed for various malignancies. This phase 1 study examined the maximum-tolerated dose (MTD), safety and pharmacokinetic/pharmacodynamic profiles of alvespimycin in patients with advanced acute myeloid leukemia (AML). Patients with advanced AML received escalating doses of intravenous alvespimycin (8–32 mg/m2), twice weekly, for 2 of 3 weeks. Dose-limiting toxicities (DLTs) were assessed during cycle 1. A total of 24 enrolled patients were evaluable for toxicity. Alvespimycin was well tolerated; the MTD was 24 mg/m2 twice weekly. Common toxicities included neutropenic fever, fatigue, nausea and diarrhea. Cardiac DLTs occurred at 32 mg/m2 (elevated troponin and myocardial infarction). Pharmacokinetics revealed linear increases in Cmax and area under the curve (AUC) from 8 to 32 mg/m2 and minor accumulation upon repeated doses. Pharmacodynamic analyses on day 15 revealed increased apoptosis and Hsp70 levels when compared with baseline within marrow blasts. Antileukemia activity occurred in 3 of 17 evaluable patients (complete remission with incomplete blood count recovery). The twice-weekly administered alvespimycin was well tolerated in patients with advanced AML, showing linear pharmacokinetics, target inhibition and signs of clinical activity. We determined a recommended phase 2 dose of 24 mg/m2.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Powers MV, Workman P . Inhibitors of the heat shock response: biology and pharmacology. FEBS Lett 2007; 581: 3758–3769.

    Article  CAS  Google Scholar 

  2. Nimmanapalli R, O’Bryan E, Bhalla K . Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res 2001; 61: 1799–1804.

    CAS  Google Scholar 

  3. Pearl LH, Prodromou C, Workman P . The Hsp90 molecular chaperone: an open and shut case for treatment. Biochem J 2008; 410: 439–453.

    Article  CAS  Google Scholar 

  4. Whitesell L, Lindquist SL . HSP90 and the chaperoning of cancer. Nat Rev Cancer 2005; 5: 761–772.

    Article  CAS  Google Scholar 

  5. Solit DB, Ivy SP, Kopil C, Sikorski R, Morris MJ, Slovin SF et al. Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer. Clin Cancer Res 2007; 13: 1775–1782.

    Article  CAS  Google Scholar 

  6. Ramanathan RK, Egorin MJ, Eiseman JL, Ramalingam S, Friedland D, Agarwala SS et al. Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers. Clin Cancer Res 2007; 13: 1769–1774.

    Article  CAS  Google Scholar 

  7. Kaur G, Belotti D, Burger AM, Fisher-Nielson K, Borsotti P, Riccardi E et al. Antiangiogenic properties of 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin: an orally bioavailable heat shock protein 90 modulator. Clin Cancer Res 2004; 10: 4813–4821.

    Article  CAS  Google Scholar 

  8. Smith V, Sausville EA, Camalier RF, Fiebig HH, Burger AM . Comparison of 17-dimethylaminoethylamino-17-demethoxy-geldanamycin (17DMAG) and 17-allylamino-17-demethoxygeldanamycin (17AAG) in vitro: effects on Hsp90 and client proteins in melanoma models. Cancer Chemother Pharmacol 2005; 56: 126–137.

    Article  CAS  Google Scholar 

  9. Murgo AJ, Kummar S, Gardner ER . Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) administered twice weekly [abstract]. J Clin Oncol 2007; 25: 3566.

    Google Scholar 

  10. Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003; 21: 4642–4649.

    Article  Google Scholar 

  11. Faderl S, Talpaz M, Estrov Z, Kantarjian HM . Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207–219.

    Article  CAS  Google Scholar 

  12. Bareng J, Jilani I, Gorre M, Kantarjian H, Giles F, Hannah A et al. A potential role for HSP90 inhibitors in the treatment of JAK2 mutant-positive diseases as demonstrated using quantitative flow cytometry. Leuk Lymphoma 2007; 48: 2189–2195.

    Article  CAS  Google Scholar 

  13. Banerji U, O’Donnell A, Scurr M, Pacey S, Stapleton S, Asad Y et al. Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies. J Clin Oncol 2005; 23: 4152–4161.

    Article  CAS  Google Scholar 

  14. Grandage VL, Linch DC, Khwaja A . PI3 kinase is constitutively active in primary acute myeloid leukaemias and regulates survival and chemoresistance via NFkB, MAP Kinase and p53 pathways [abstract]. Blood 2003; 102: 2156.

    Article  Google Scholar 

  15. Kornblau SM, Womble M, Qiu YH, Jackson CE, Chen W, Konopleva M et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006; 108: 2358–2365.

    Article  CAS  Google Scholar 

  16. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001; 98: 1752–1759.

    Article  CAS  Google Scholar 

  17. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002; 100: 59–66.

    CAS  Google Scholar 

  18. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002; 99: 4326–4335.

    Article  CAS  Google Scholar 

  19. Towatari M, Iida H, Iwata H, Hamaguchi M, Saito H . Constitutive activation of mitogen-activated protein kinase pathway in acute leukemia cells. Leukemia 1997; 11: 479–484.

    Article  CAS  Google Scholar 

  20. Cairoli R, Cairoli R, Beghini A, Grillo G, Nadali G, Elice F et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006; 107: 3463–3468.

    Article  CAS  Google Scholar 

  21. Paschka P, Marcucci G, Ruppert AS, Mrózek K, Chen H, Kittles RA et al. Adverse prognostic significance of kit mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006; 24: 3904–3911.

    Article  CAS  Google Scholar 

  22. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006; 107: 1791–1799.

    Article  CAS  Google Scholar 

  23. Thomas X, Campos L, Le QH, Guyotat D . Heat shock proteins and acute leukemias. Hematology 2005; 10: 225–235.

    Article  CAS  Google Scholar 

  24. Ferrarini M, Heltai S, Zocchi MR, Rugarli C . Unusual expression and localization of heat-shock proteins in human tumor cells. Int J Cancer 1992; 51: 613–619.

    Article  CAS  Google Scholar 

  25. Piloto O, Wright M, Brown P, Kim KT, Levis M, Small D . Prolonged exposure to FLT3 inhibitors leads to resistance via activation of parallel signaling pathways. Blood 2007; 109: 1643–1652.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by Kosan Biosciences, Hayward, CA, USA.

We thank Michelle Mintz, ARNP, for her excellent care of the patients. We also thank Rasa Hamilton for assistance in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. H Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA

    J E Lancet & M Burton

  2. University of Maryland, Greenebaum Center, Baltimore, MD, USA

    I Gojo, M Quinn & M R Baer

  3. Roswell Park Cancer Institute, Buffalo, NY, USA

    S M Tighe & M R Baer

  4. Kosan Biosciences, Hayward, CA, USA

    K Kersey, Z Zhong & A L Hannah

  5. Department of Hematopathology, Nichols Institute, San Juan Capistrano, CA, USA

    M X Albitar

  6. Medical College of Georgia Cancer Center, Augusta, GA, USA

    K Bhalla

Authors
  1. J E Lancet
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Gojo
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Burton
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Quinn
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S M Tighe
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. K Kersey
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Z Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M X Albitar
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. K Bhalla
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A L Hannah
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. M R Baer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J E Lancet.

Ethics declarations

Competing interests

MX Albitar and AL Hannah are former Kosan consultants (compensated), and K Kersey and Z Zhong are former Kosan employees.

Additional information

Presented in abstract form at the 48th annual meeting of the American Society of Hematology, Orlando, FL, 10 December 2006.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lancet, J., Gojo, I., Burton, M. et al. Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699–705 (2010). https://doi.org/10.1038/leu.2009.292

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2009.292

Keywords

Search

Advanced search

Quick links